Stamler et all argue that a low cholesterol level is not the cause of the increased mortality seen in population studies but is a marker for causative factors. They are probably right, but they disregard that a high cholesterol level may also be a marker only. Smoking,2 obesity,3 lack of exercise,4 and psychological stress,5 for instance, increase blood cholesterol but may cause coronary heart disease by other mechanisms.
The crucial point is that lowering cholesterol actively increases noncoronary mortality, and this increase is not balanced by a decrease of coronary mortality.67 Stamler et all claim that the increased mortality found in the meta-analyses is due to selection of trials. They are wrong, because the excluded trials were mostly unsupportive. 8 Stamler et al' are skeptical of meta-analysis and use instead the results from only three trials to argue for a "healthier" level of serum cholesterol. The effects of the two largest trials were pathetic, however, and as all of them were multifactorial, their effect, if any, may have been due to other causes than cholesterol lowering.
In a recent meta-analysis of 35 cholesterol-lowering trials, mortality decreased in a subgroup of trials including 5116 individuals.7 But mortality increased in a much larger subgroup of 27 918 individuals. The first subgroup was called a high-risk group and the other one a low-risk group, according to the mortality of the control subjects. But how should we classify before treatment?9 Several trials in the so-called low-risk group were secondary preventive, and the mean cholesterol level was higher (7.15 mmol/L) than in the so-called high-risk group (6.72 mmol/L). Thus, when Stamler et al say that only those at highest risk should be treated, they impose an impossible mission on physicians. The risk is greater that we will shorten the lives of our patients instead of prolonging them.
Stamler et all think that the increased mortality after drug treatment should be prevented by careful monitoring. However, I am confident that the trial directors monitored their patients carefully, probably more carefully than we physicians do, and yet mortality increased. There are also obvious methodologic problems connected with the prevention of cancer, violence, and other unexpected causes of death.
Finally, Stamler et all stress the importance of diet. It is true that trials using an extreme diet or trials on patients in mental hospitals have lowered the cholesterol level significantly, but it is unrealistic to think that healthy people should accept these rigorous diets during many years. In trials where a more palatable diet was used, the effect on blood cholesterol has been trivial despite intensive counseling. In MRFIT,10 for instance, cholesterol was lowered by 2%, in the WHO study'1 by 1%, and in the Gothenburg trial'2 by even less. In the Helsinki study,'3 the control group was treated by diet, but their cholesterol increased. Note also that a significant reduction of nonfatal coronary heart disease has not been achieved in dietary trials. 8 The right thing to do is to stop the cholesterol campaign. The evidence for a causal relation among atherogenic diet, high serum cholesterol, and coronary disease is far from overwhelming. On the contrary, a host of studies have shown many inconsistencies with this idea. ' 3 , related to meta-analyses of data from randomized controlled trials (RCTs) of cholesterol lowering. Olson and Ravnskov also rely heavily on these meta-analyses as a basis for their critiques of our editorial and of US national policy on serum cholesterol.
Altogether, their three letters cite findings in 8 such metaanalyses (of 6 to 35 trials).3-10 However, the fact is that all these meta-analyses are at best irrelevant or at worst misleading in regard to recommended dietary approaches for CHD primary prevention. Specifically, of the cited unifactorial trials on CHD primary prevention, only two were dietary trials. All others were drug trials, hence by definition unrelated to the main thrust, that is, the nutritional emphasis, of US national policy. Lumping diet and drug RCTs together is a flawed use of the meta-analysis method, and citing overall findings from such meta-analyses is inappropriate when the primary issue under discussion is national nutritional policy. Moreover, combining all these RCTs results in ignoring the details of their nature, design, procedure, and outcome that are critical for assessment of their soundness and policy relevance.
As to specifics, first on the two unifactorial diet trials,1""12 both were actually combined primary and secondary prevention trials. Both had design features that make their findings uninformative in regard to public policy on reduction of coronary and all-cause
